Premaitha Health PLC Result of AGM (6631N)
28 October 2016 - 2:10AM
UK Regulatory
TIDMNIPT
RNS Number : 6631N
Premaitha Health PLC
27 October 2016
Premaitha Health Plc
("Premaitha" or the "Company")
Result of AGM
Manchester, UK - 27 October 2016 - Premaitha announces that at
the Annual General Meeting of the Company held earlier today, all
resolutions were duly passed.
For more information, please contact:
Premaitha Health plc Tel: +44 (0)
161 667 1053
Dr Stephen Little, Chief Executive
Office
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)
20 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: +44 (0)
20 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
20 7830 9704
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is a molecular diagnostics company which uses the
latest advances in DNA analysis technology to develop safer, faster
and regulatory approved non-invasive screening tests for pregnant
women.
Premaitha's lead test - the IONA(R) test - was launched in
February 2015 and is the leading CE marked complete system which
estimates the risk of a fetus being affected with Down's syndrome
or other genetic conditions. The IONA(R) test is performed on the
mother's blood sample - which contains traces of fetal DNA - and
then analysed using next generation DNA sequencing technology from
ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary stressful and invasive
follow-up diagnostic procedures which are costly, resource
intensive and carry a risk of miscarriage.
Non-invasive prenatal screening is an emerging, multi-billion
dollar global market and Premaitha's complete CE marked system
enables laboratories and health care practitioners to offer an
approved, non-invasive prenatal screening system in-house.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGFEFFIWFMSESS
(END) Dow Jones Newswires
October 27, 2016 11:10 ET (15:10 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024